Eva Kassi
Overview
Explore the profile of Eva Kassi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
115
Citations
1883
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bourganou M, Chondrogianni M, Kyrou I, Flessa C, Chatzigeorgiou A, Oikonomou E, et al.
Int J Mol Sci
. 2025 Feb;
26(4).
PMID: 40004054
Non-alcoholic fatty liver disease (NAFLD), now referred to as metabolic dysfunction-associated steatotic liver disease (MASLD), is the most prevalent liver disorder globally, linked to obesity, type 2 diabetes, and cardiovascular...
2.
Giannakodimos A, Oikonomou E, Pantelidis P, Theofilis P, Katsiki N, Goliopoulou A, et al.
Expert Rev Gastroenterol Hepatol
. 2025 Feb;
:1-14.
PMID: 39988816
Introduction: The purpose of this systematic review and meta-analysis is to investigate the association of metabolic dysfunction-associated steatotic liver disease (MASLD) with arterial stiffness and enlighten on potential cardiometabolic co-factors....
3.
Antoniou E, Oikonomou E, Theofilis P, Lambadiari V, Kassi E, Chasikidis C, et al.
Microrna
. 2025 Feb;
PMID: 39936443
Introduction: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is a major contributor to global morbidity and mortality. As diagnostic tools for MASLD remain limited, microRNAs (miRs) have garnered attention as promising...
4.
Velliou R, Giannousi E, Ralliou C, Kassi E, Chatzigeorgiou A
Cells
. 2024 Nov;
13(22).
PMID: 39594577
Metabolic dysfunction-associated fatty liver disease (MASLD) presents a growing global health challenge with limited therapeutic choices. This review delves into the array of ex vivo tools and models utilized in...
5.
Psachna S, Chondrogianni M, Stathopoulos K, Polymeris A, Chatzigeorgiou A, Chronopoulos E, et al.
Endocrine
. 2024 Oct;
87(3):907-919.
PMID: 39402366
Diabetes mellitus (DM) is a complex metabolic disorder characterized by chronic hyperglycemia, which derives from either insufficient insulin production [type 1 diabetes mellitus (T1DM)] or both impaired insulin sensitivity along...
6.
Vlachogiannis N, Legaki A, Kassi E, Mikelis C, Tentolouris N, Sfikakis P, et al.
Thromb Haemost
. 2024 Oct;
PMID: 39401520
No abstract available.
7.
Chamakioti M, Chrousos G, Kassi E, Vlachakis D, Yapijakis C
Int J Mol Sci
. 2024 Aug;
25(15).
PMID: 39125827
Exosomes, natural nanovesicles that contain a cargo of biologically active molecules such as lipids, proteins, and nucleic acids, are released from cells to the extracellular environment. They then act as...
8.
Katsarou A, Tsioulos G, Kassi E, Chatzigeorgiou A
Hormones (Athens)
. 2024 Aug;
23(4):621-636.
PMID: 39112786
Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease, with its incidence increasing in parallel with the global prevalence of obesity and type 2 diabetes mellitus. Despite our steadily...
9.
Leca B, Lagojda L, Kite C, Karteris E, Kassi E, Randeva H, et al.
Expert Rev Endocrinol Metab
. 2024 Jun;
19(4):335-348.
PMID: 38860684
Introduction: Obesity and metabolic-associated fatty liver disease (MAFLD) during pregnancy constitute significant problems for routine antenatal care, with increasing prevalence globally. Similar to obesity, MAFLD is associated with a higher...
10.
Abdelhameed F, Kite C, Lagojda L, Dallaway A, Chatha K, Chaggar S, et al.
Curr Obes Rep
. 2024 May;
13(3):510-531.
PMID: 38809396
Purpose Of Review: The prevalence of non-alcoholic fatty liver disease (NAFLD) is rapidly increasing worldwide, making it the leading cause of liver related morbidity and mortality. Currently, liver biopsy is...